Psychopharmacology

Interdisciplinary Studies Program
Barcelona, Spain

Dates: 1/3/24 - 4/27/24

Interdisciplinary Studies

Psychopharmacology

Psychopharmacology Course Overview

OVERVIEW

CEA CAPA Partner Institution: Pompeu Fabra University
Location: Barcelona, Spain
Primary Subject Area: Neuroscience
Instruction in: English
Transcript Source: Partner Institution
Course Details: Level 300
Recommended Semester Credits: 3
Contact Hours: 45

DESCRIPTION

The purpose of this course is to understand the essential foundations of psychopharmacology from a neurobiological perspective. It is intended that the student learn the basis of psychoactive drugs, to understand their mechanism of action, distinguish between therapeutic and side effects, know the main drugs that are subject to abuse, know the addictive and neurotoxic potential of some psychoactive drugs, and learn about current drug addiction treatments. To achieve these goals, a neural circuit view will be used, and behavioral alterations in psychopathology and the genetic basis of normal and pathological behavior will be considered. The competences to be achieved include identifying, describing and relating behavioral neurobiology to psychopharmacology, using different information and communication technologies for diverse purposes, working in groups and presenting the main ideas of a topic. The course will address the neurobiological mechanisms and treatment of psychiatric illnesses such as schizophrenia, depression, anxiety and addiction. To understand the neurobiological substrate of mental processes and behavior, it is necessary to know the components and functioning of the nervous system. The course aims to provide the knowledge needed to understand how the brain works in health and disease. This will include the study of the neuron and its neurochemical physiology. At the end of this course, the student will gain valuable knowledge of psychopharmacology and neuroscience useful for daily life.


Get a Flight Credit worth up to $1,250 when you apply with code* by June 30, 2025